Literature DB >> 9834083

Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.

W E Fogler1, K Volker, M Watanabe, J M Wigginton, P Roessler, M J Brunda, J R Ortaldo, R H Wiltrout.   

Abstract

NK cells have been shown to be important antitumor or antiviral effector cells in the liver. In the present study we have examined the factors that regulate the initial recruitment and subsequent fate of hepatic NK and T cells in mice treated with IL-12 or IL-2. Daily administration of IL-12 caused a rapid initial increase in NK cells followed by a subsequent decrease that coincided with an accumulation of T cells. The recruitment of hepatic NK cells by IL-12, but not the subsequent T cell infiltrate, was abrogated in IFN-gamma(-/-) mice. In contrast, daily administration of IL-2 caused a sustained increase in liver-associated NK cells that was not diminished in IFN-gamma(-/-) mice. The IL-12-induced recruitment in both hepatic NK and T cells was abrogated by in vivo treatment with anti-VCAM-1 mAbs, while treatment with anti-ICAM-1 Abs decreased only the recruitment of T cells in the IL-12-treated mice. The rapid loss of newly recruited hepatic NK cells in IL-12-treated mice did not occur in SCID mice or in B.MRL-Fas(lpr) (Fas-) and B6Smn.C3H-Fasl(gld) (FasL-) mutant mice, suggesting that T cells can actively eliminate hepatic NK cells through a Fas-dependent mechanism. These findings also imply that during the endogenous innate immune response to infectious agents or tumors or in the host response induced by cytokine therapies, the biologic effects of NK cells may be limited by T cell-mediated effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834083

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Authors:  Qun Jiang; Jonathan M Weiss; Timothy Back; Tim Chan; John R Ortaldo; Sylvie Guichard; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

2.  Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.

Authors:  David A Zaharoff; Kenneth W Hance; Connie J Rogers; Jeffrey Schlom; John W Greiner
Journal:  J Immunother       Date:  2010-09       Impact factor: 4.456

3.  T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria.

Authors:  Carmen M Collazo; Anda I Meierovics; Roberto De Pascalis; Terry H Wu; C Rick Lyons; Karen L Elkins
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 5.  Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

Authors:  Jeff J Subleski; Robert H Wiltrout; Jonathan M Weiss
Journal:  J Autoimmun       Date:  2009-08-13       Impact factor: 7.094

6.  Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.

Authors:  Stephen R Goding; Shaohong Yu; Lisa M Bailey; Michael T Lotze; Per H Basse
Journal:  Clin Immunol       Date:  2016-07-01       Impact factor: 3.969

Review 7.  Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases.

Authors:  Bin Gao; Svetlana Radaeva; Ogyi Park
Journal:  J Leukoc Biol       Date:  2009-09       Impact factor: 4.962

8.  Nitric oxide is a key component in inflammation-accelerated tumorigenesis.

Authors:  S Perwez Hussain; Peijun He; Jeffery Subleski; Lorne J Hofseth; Glenwood E Trivers; Leah Mechanic; Anne B Hofseth; Mark Bernard; Jonathan Schwank; Giang Nguyen; Ewy Mathe; Draginja Djurickovic; Diana Haines; Jonathan Weiss; Timothy Back; Eilene Gruys; Victor E Laubach; Robert H Wiltrout; Curtis C Harris
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

9.  Natural killer cell activation contributes to hepatitis B viral control in a mouse model.

Authors:  Shiwen Tong; Guangze Liu; Minghong Li; Xiumei Li; Qian Liu; Hong Peng; Shiying Li; Hong Ren; Wenwei Yin
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

Review 10.  Interleukin 12: still a promising candidate for tumor immunotherapy?

Authors:  Witold Lasek; Radosław Zagożdżon; Marek Jakobisiak
Journal:  Cancer Immunol Immunother       Date:  2014-02-11       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.